Serum chemokine IL-8 acts as a biomarker for identifying COVID-19-associated persistent severe acute kidney injury
Objectives Persistent severe acute kidney injury (PS-AKI) is associated with poor clinical outcomes. Our study attempted to evaluate the diagnostic value of chemokines for early-stage PS-AKI prediction.Methods According to the KDIGO criteria, 115 COVID-19 patients diagnosed with stage 2/3 AKI were r...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2311316 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591138954936320 |
|---|---|
| author | Zhi He Jing-jing Liu Shao-lei Ma |
| author_facet | Zhi He Jing-jing Liu Shao-lei Ma |
| author_sort | Zhi He |
| collection | DOAJ |
| description | Objectives Persistent severe acute kidney injury (PS-AKI) is associated with poor clinical outcomes. Our study attempted to evaluate the diagnostic value of chemokines for early-stage PS-AKI prediction.Methods According to the KDIGO criteria, 115 COVID-19 patients diagnosed with stage 2/3 AKI were recruited from the intensive care unit between December 2022 and February 2023. Primary clinical outcomes included detecting PS-AKI in the first week (≥ KDIGO stage 2 ≥ 72 h). Cytometric Bead Array was used to detect patient plasma levels (interleukin-8 (IL-8), C-C chemokine ligand 5 (CCL5), chemokine (C-X-C Motif) ligand 9 (CXCL9), and interferon-inducible protein 10 (IP-10)) of chemokines within 24 h of enrollment.Results Of the 115 COVID-19 patients with stage 2/3 AKI, 27 were diagnosed with PS-AKI. Among the four measured chemokines, only the IL-8 level was significantly elevated in the PS-AKI group than in the Non-PS-AKI group. IL-8 was more effective as a biomarker while predicting PS-AKI with an area under the curve of 0.769 (0.675-0.863). This was superior to other biomarkers related to AKI, including serum creatinine. Moreover, plasma IL-8 levels of >32.2 pg/ml on admission could predict PS-AKI risk (sensitivity = 92.6%, specificity = 51.1%). Additionally, the IL-8 level was associated with total protein and IL-6 levels.Conclusion Plasma IL-8 is a promising marker for the early identification of PS-AKI among COVID-19 patients. These findings should be validated in further studies with a larger sample size. |
| format | Article |
| id | doaj-art-f7071086dba7487586678ea943a73715 |
| institution | Kabale University |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-f7071086dba7487586678ea943a737152025-01-23T04:17:49ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492024-12-0146110.1080/0886022X.2024.2311316Serum chemokine IL-8 acts as a biomarker for identifying COVID-19-associated persistent severe acute kidney injuryZhi He0Jing-jing Liu1Shao-lei Ma2Center of Clinical Laboratory Medicine, Zhongda Hospital, Southeast University, Nanjing, ChinaCenter of Clinical Laboratory Medicine, Zhongda Hospital, Southeast University, Nanjing, ChinaDepartment of Emergency and Critical Care Medicine, Zhongda Hospital, Southeast University, Nanjing, ChinaObjectives Persistent severe acute kidney injury (PS-AKI) is associated with poor clinical outcomes. Our study attempted to evaluate the diagnostic value of chemokines for early-stage PS-AKI prediction.Methods According to the KDIGO criteria, 115 COVID-19 patients diagnosed with stage 2/3 AKI were recruited from the intensive care unit between December 2022 and February 2023. Primary clinical outcomes included detecting PS-AKI in the first week (≥ KDIGO stage 2 ≥ 72 h). Cytometric Bead Array was used to detect patient plasma levels (interleukin-8 (IL-8), C-C chemokine ligand 5 (CCL5), chemokine (C-X-C Motif) ligand 9 (CXCL9), and interferon-inducible protein 10 (IP-10)) of chemokines within 24 h of enrollment.Results Of the 115 COVID-19 patients with stage 2/3 AKI, 27 were diagnosed with PS-AKI. Among the four measured chemokines, only the IL-8 level was significantly elevated in the PS-AKI group than in the Non-PS-AKI group. IL-8 was more effective as a biomarker while predicting PS-AKI with an area under the curve of 0.769 (0.675-0.863). This was superior to other biomarkers related to AKI, including serum creatinine. Moreover, plasma IL-8 levels of >32.2 pg/ml on admission could predict PS-AKI risk (sensitivity = 92.6%, specificity = 51.1%). Additionally, the IL-8 level was associated with total protein and IL-6 levels.Conclusion Plasma IL-8 is a promising marker for the early identification of PS-AKI among COVID-19 patients. These findings should be validated in further studies with a larger sample size.https://www.tandfonline.com/doi/10.1080/0886022X.2024.2311316covid-19acute kidney injuryIL-8IP-10biomarker |
| spellingShingle | Zhi He Jing-jing Liu Shao-lei Ma Serum chemokine IL-8 acts as a biomarker for identifying COVID-19-associated persistent severe acute kidney injury Renal Failure covid-19 acute kidney injury IL-8 IP-10 biomarker |
| title | Serum chemokine IL-8 acts as a biomarker for identifying COVID-19-associated persistent severe acute kidney injury |
| title_full | Serum chemokine IL-8 acts as a biomarker for identifying COVID-19-associated persistent severe acute kidney injury |
| title_fullStr | Serum chemokine IL-8 acts as a biomarker for identifying COVID-19-associated persistent severe acute kidney injury |
| title_full_unstemmed | Serum chemokine IL-8 acts as a biomarker for identifying COVID-19-associated persistent severe acute kidney injury |
| title_short | Serum chemokine IL-8 acts as a biomarker for identifying COVID-19-associated persistent severe acute kidney injury |
| title_sort | serum chemokine il 8 acts as a biomarker for identifying covid 19 associated persistent severe acute kidney injury |
| topic | covid-19 acute kidney injury IL-8 IP-10 biomarker |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2311316 |
| work_keys_str_mv | AT zhihe serumchemokineil8actsasabiomarkerforidentifyingcovid19associatedpersistentsevereacutekidneyinjury AT jingjingliu serumchemokineil8actsasabiomarkerforidentifyingcovid19associatedpersistentsevereacutekidneyinjury AT shaoleima serumchemokineil8actsasabiomarkerforidentifyingcovid19associatedpersistentsevereacutekidneyinjury |